Summary
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Official Title
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2
Keywords
Narcolepsy Type 2, Narcolepsy, NT2, Orexin-2 receptor agonist, Sleep, Sleep disorder, Excessive daytime sleepiness, Sleep Wake Disorders, Disorders of Excessive Somnolence, Counterfeit Drugs, ALKS 2680, ALKS 2680, 10 mg, ALKS 2680, 14 mg, ALKS 2680, 18 mg